PDCD1 and acral lentiginous melanoma: Additionally, a meta-analysis of 19 studies with 646 patients with metastatic ALM exploring systemic treatment outcomes showed that patients treated with anti-PD-1 monotherapy had higher rates of OS (53%) compared with anti-CTLA-4 monotherapy (34%) (p < 0.001) [68].